# EDGAR Filing Document

**Accession Number:** 0001644963
**File Stem:** 0001104659-23-004095
**Filing Date:** 2023-1
**Character Count:** 3260
**Document Hash:** 668976ff4779130b7b056b6ef12bc732
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-004095.hdr.sgml**: 20230117

**ACCESSION NUMBER**: 0001104659-23-004095

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230117

**DATE AS OF CHANGE**: 20230117

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AVENUE THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001644963
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 474113275
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38114
- **FILM NUMBER:** 23530431

**BUSINESS ADDRESS:**
- **STREET 1:** 1111 KANE CONCOURSE
- **STREET 2:** SUITE 301
- **CITY:** BAY HARBOR ISLANDS
- **STATE:** FL
- **ZIP:** 33154
- **BUSINESS PHONE:** 781-652-4500

**MAIL ADDRESS:**
- **STREET 1:** 1111 KANE CONCOURSE
- **STREET 2:** SUITE 301
- **CITY:** BAY HARBOR ISLANDS
- **STATE:** FL
- **ZIP:** 33154

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549**

**SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a) of the<br> Securities Exchange Act of 1934<br> (Amendment No.)**

Filed by the Registrant. ⌧ <br> Filed by a Party other than the Registrant ◻

Check the appropriate box:

---

| | |
|:---|:---|
| ◻ | Preliminary Proxy Statement |
| ◻ | **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** |
| ◻ | Definitive Proxy Statement |
| ⌧ | Definitive Additional Materials |
| ◻ | Soliciting Material under §240.14a-12 |

---

**AVENUE THERAPEUTICS, INC.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

⌧ No fee required

◻ Fee paid previously with preliminary materials.

◻ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

*The following is a letter sent to certain shareholders of Avenue Therapeutics, Inc. in a mailing commenced on January 17, 2023*

![](tm233526d1_defa14aimg01.jpg)

Dear Avenue Therapeutics' Shareholder:

**YOUR PARTICIPATION IS IMPORTANT – PLEASE VOTE TODAY!**

According to our latest records, your proxy vote relating to the Avenue Therapeutics' Annual Meeting of Stockholders has not yet been received.

&nbsp;&nbsp;**You have until January 29, 2023 at 11:59 p.m. EST to vote your shares.<br> PLEASE VOTE TODAY following the instructions on your proxy card.**

---

| | | |
|:---|:---|:---|
| Item 1 | ELECTION OF DIRECTORS | Vote FOR |
| Item 2 | RATIFY BDO USA, LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTANT | Vote FOR |
| Item 3 | APPROVE AN AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK | Vote FOR |
| Item 4 | APPROVE AN AMENDMENT TO OUR 2015 EQUITY INCENTIVE PLAN | Vote FOR |

---

If you have any questions please contact our proxy solicitor, Alliance Advisors, toll free at: 1-855-506-1762

If you have recently mailed your proxy card or cast your vote by phone or internet, please accept our thanks and disregard this request.

Sincerely,

**Alexandra MacLean, M.D.** 

Chief Executive Officer